New Data Support 24-Week Abrocitinib Tapering in Controlled AD
Key Takeaways
- Most patients with well-controlled moderate-to-severe atopic dermatitis successfully maintained disease control during 24 weeks of abrocitinib tapering.
- Both dose reduction and interval extension reduced medication exposure and treatment costs, although interval extension was associated with more regimen changes due to disease fluctuation.
- The findings support tapering as a potential option for selected patients but require confirmation in larger prospective studies.
New data published in the Journal of the American Academy of Dermatology suggests tapering abrocitinib may be a feasible strategy for patients with moderate-to-severe atopic dermatitis (AD) who have achieved an adequate clinical response.
Investigators evaluated 78 patients who tapered abrocitinib over 24 weeks using either dose reduction (n = 36) or interval extension (n = 42). Most (97.4%) of patients successfully completed tapering, with nonrelapse rates of 97.4% at week 12 and 91.0% at week 24. Tapering substantially reduced treatment burden, lowering the cumulative abrocitinib dose by nearly 10 g over 24 weeks compared with standard therapy and reducing medication costs. While both tapering approaches maintained disease control, patients assigned to interval extension were significantly more likely to switch strategies because of disease fluctuations than those undergoing dose reduction (28.6% vs 8.3%; P = 0.041). Factors limiting applicability of the data included study's single-center, retrospective design, relatively small cohort, and limited follow-up.
"Twenty-four-week abrocitinib tapering appears feasible in well-responding moderate-to-severe AD patients, reducing treatment burden while preserving efficacy," the investigators concluded.
Source
Deng S, et al. JAAD. 2026. Doi:10.1016/j.jaad.2026.06.064